entertainment -WSS

entertainment

author：fashion 2025-09-06 03:17:28 - browse：54

Earlier this month, Intellia Therapeutics announced it was scrapping plans to include U.S.-based sites in one of its mid-stage CRISPR trials after the Food and Drug Administration requested additional data to support including female patients of childbearing potential. The move left many researchers wondering whether the specter of accidental germline transmission — which haunted early gene therapy trials — had now risen over the field of gene editing.

Over the weekend, Intellia sought to assure the gene editing community that no such thing is happening. At a meeting at Cold Spring Harbor Laboratory that drew more than 400 of the field’s top scientists, the company shared more detailed information about studies it has conducted to assess the risks that renegade CRISPR components could be getting into an egg or sperm. These studies demonstrate “that there’s no evidence of vertical germline transmission of those edits,” Jonathan Phillips, head of pharmacology and toxicology at Intellia, said during a presentation Saturday.

Intellia is one of the leading companies working to advance in vivo gene editing therapies. In a landmark study published in the New England Journal of Medicine in 2021, Intellia revealed data from six patients in its trial for a transthyretin amyloidosis therapy — showing for the first time that it was possible to precisely alter the DNA of particular cells within the human body to treat disease with a one-time infusion of CRISPR. Included in the supplementary material was a redacted version of the company’s package requesting authorization to start its clinical trial. It noted that during toxicology studies in non-human primates, Intellia scientists discovered that editing had taken place at low levels in organs other than the liver, including the spleen and adrenal glands. In three out of 12 female monkeys, they also found editing in the animals’ ovaries.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Idaho abortion case may prompt more restrictions in other states

focus

WSS

Florida health officials providing scant details on measles cases

He's 19 months old and has one of the world’s rarest diseases

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Stem cell biologist probes earliest stages of human development

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Fauci’s Covid grilling leads GOP to weigh foreign research rules

leisure time

entertainment

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Longer MASH drug regimen improved liver, Akero study finds

Medicare proposal to cover medical devices draws a mixed reaction

State of the Union pitch: Bigger Medicare drug price negotiations

As demand for Covid shots wanes, Moderna seeks its next success

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Heart attack and stroke risk calculators need revising

New menopause drug shows promise in relief for hot flashes

At least 13 dead in Texas as scorching temps continue

DeSantis can now import cheaper drugs. But will Biden get credit?

hotspot

Immune cells and nerve overgrowth may explain recurring UTI pain

Biden's 'march

The SUPPORT Act is critical to fighting the opioid crisis

Biden's 'march

Heart disease and mental health: A look at cardiac psychology

Idaho abortion case may prompt more restrictions in other states

leisure time

Wikipedia

focus

hotspot